Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)

Age
18 years - 99 years
Gender
All
Location
1
Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)

Brief description of study

This is a randomized phase 2 open label study of sacituzumab govitecan +/- pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer and who have not received a prior PD-1/L1 inhibitor

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older, Breast Cancer

Updated on 04 Aug 2024. Study ID: 850026
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research